Drug Discovery · Cambridge, MA · Founded 2015 · Privately Held (backing)
Developer of cell-penetrating mini proteins (CPMPs) designed to target cancer-causing proteins inside cancer cells and neutralize them. Parabilis Medicines is based in Cambridge, MA and was founded in 2015. It is valued at about $920 million as of Oct 2026, set by institutional fund marks. It has raised $812 million across 3 recorded rounds; the latest was a $305 million Series F in Jan 2026.
PMV mark · valuation
$920.0M
Oct 2026
Priced at
its later-stage round
Jan 2026
Total raised
$812.0M
Last round
Later Stage VC (Series F)
Jan 2026
No prints on record
No secondary trades in Parabilis Medicines shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Parabilis Medicines stock.
